The Ultimate Fighting Championship (UFC) and Venum have extended their global partnership for several more years.
The agreement between the French brand and the MMA entity comes ahead of the UFC's first event in France, which will take place on September 3rd at Paris' Accor Arena.
The brand will continue to design, manufacture, and distribute the promotion's performance apparel for the duration of the new contract, which is expected to be three years.
While not as large as the UFC's previous six-year, US$70 million contract with Reebok, Venum guaranteed fighters an increase in fees ranging from US$500 to US$2,000 depending on experience.
Tracey Bleczinski, UFC’s senior vice president of global consumer products, described Venum as an iconic combat sports brand that understands the unique needs of MMA athletes.
The UFC official added that the feedback on the Venum-designed fight kits and apparel's craftsmanship, style, and performance has been tremendous.


J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Oil Prices Steady as Strait of Hormuz Traffic Slows Amid US-Iran Conflict
Canada-US Trade Talks Gain Momentum Ahead of Aug. 19 Tariff Deadline
Morgan Stanley Sees Fed Holding Rates as U.S. Inflation Cools
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan
Japan Economy Grows 1.1% in Q2 as Consumer Spending Stalls
White House Defends Trump’s FIFA Peace Prize Amid Global Criticism
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories
Spying, Southampton and economic pressure cooker of the ‘richest match in football’
US Stock Futures Steady as Cooling Inflation and Strong Earnings Support Markets
DOJ Launches Antitrust Investigation Into the NFL Over Broadcast Restrictions
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
KOSPI Eyes Best Weekly Gain Since June as Samsung, SK Hynix Rally 



